Virtual specialty care platform AmplifyMD, which aims to help hospitals do more with fewer doctors, scored $20 million dollars this Wednesday in a Series B financing round led by Forerunner Ventures.

The FDA has approved a Novartis drug for chronic spontaneous urticaria (CSU), providing patients an oral treatment alternative to currently available injectable medications. The regulatory decision ...

A Pharvaris drug led to speedy relief and symptom resolution from the sudden swelling attacks caused by a rare genetic disorder, preliminary Phase 3 clinical trial results that pave the way for an FDA ...

The next phase of AI in healthcare is about building systems where human clinicians, supervisors, and AI can all contribute, ...

While the policy changes create new opportunities, they also introduce operational complexity. Here's some important things ...

The true promise of AI lies not in autonomy of either the clinician or machine, but in a balanced collaboration that bolsters ...

Elevance Health is leveraging AI for simplifying the member experience, improving the provider experience and making sure ...

Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration's approach to ...

New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial ...

UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a move that follows the ...

The healthcare affordability crisis in the U.S. has quietly become a trust crisis, with a growing share of Americans walking ...

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility ...